Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Invion ( (AU:IVX) ) has issued an update.
Invion Limited announced the issuance of 147,144 fully paid ordinary shares following the exercise of unlisted options. The company is actively exploring opportunities to expand its clinical trial and research programs into additional indications and is in discussions with RMW Cho Group Ltd to potentially extend its rights to the Photosoft™ technology. These discussions are preliminary, and there is no certainty of reaching a binding agreement. This strategic move could enhance Invion’s market position and expand its technological applications, potentially impacting stakeholders positively.
More about Invion
Invion is a life-science company specializing in the research and development of Photosoft™ technology, which is used in the treatment of various cancers. The company holds the license rights to this technology in Australia and New Zealand, with research and clinical trials funded by RMW Cho Group Limited. Invion is publicly listed on the ASX under the code IVX.
Average Trading Volume: 102,715
Technical Sentiment Signal: Sell
Current Market Cap: A$10.59M
Find detailed analytics on IVX stock on TipRanks’ Stock Analysis page.